Healthcare

LifeStance runs a large U.S. outpatient mental health network combining in-person and virtual care. Rapid revenue expansion, newly positive earnings, and much stronger cash generation make it a company worth a closer look in behavioral healthcare.

Kiniksa Pharmaceuticals has evolved into a commercial-stage biotech built around fast-growing Arcalyst sales, rising cash generation, and a very low-debt balance sheet. The next phase depends on turning that focused success into a broader immunology platform.

Integer Holdings makes critical parts and devices for major medtech companies, with especially strong exposure to cardiac and vascular care. Its niche manufacturing role, solid profitability, and presence in attractive therapy areas make its long-term profile worth a closer look.

Ionis Pharmaceuticals develops RNA-targeted medicines and pairs a deep antisense platform with major pharma partnerships, marketed products, and late-stage programs. The appeal lies in whether that scientific base can evolve into broader recurring revenue over time.

Iovance is building a commercial position in personalized cancer cell therapy, with Amtagvi giving it an early lead in TIL treatment for solid tumors. The key question is whether that first-mover edge can turn rising revenue into a durable oncology platform.

Immunovant is building a next-generation autoimmune pipeline around FcRn inhibition, with IMVT-1402 at the center. The key attraction is a validated treatment class, multiple disease opportunities, and a balance sheet carrying very little debt.

Indivior is a focused drugmaker centered on addiction treatment, with SUBLOCADE driving most of the business. Revenue and margins have improved sharply, and its position in long-acting opioid use disorder therapy gives the company a clearer long-term growth path.